EN | TR
E-ISSN: 3061-9947
Accompanying prostate pathologies in patients undergoing radical cystoprostatectomy due to bladder cancer
PDF
Cite
Share
Request
Original Article
VOLUME: 53 ISSUE: 2
P: 256-262
2020

Accompanying prostate pathologies in patients undergoing radical cystoprostatectomy due to bladder cancer

Acta Haematol Oncol Turc 2020;53(2):256-262
DOI: 10.5505/aot.2020.54765
Cevahir Özer 1
Bermal Hasbay 2
1. Department Of Urology, Baskent University Adana Dr. Turgut Noyan Medical And Research Center, Adana, Turkey
2. Department Of Patholoy, Baskent University Adana Dr. Turgut Noyan Medical And Research Center, Adana, Turkey
3.
No information available.
No information available
Received Date: 2020-06-01T12:24:45
Accepted Date: 2020-09-04T15:16:24
PDF
Cite
Share
Request

Abstract

INTRODUCTION

In this study, we aimed to evaluate the accompanying prostate pathologies in patients undergoing radical cystoprostatectomy for urothelial bladder cancer.

METHODS

In the retrospective study, 197 patients who underwent radical cystectomy due to bladder tumor between 2001 and 2019 were evaluated. Those who were operated for non-urothelial bladder cancer, women, those who underwent prostate-sparing cystectomy, and those diagnosed with prostate cancer before the operation were excluded. A total of 169 male patients who underwent radical cystoprostatectomy due to urothelial bladder tumor were included in the study.

RESULTS

The mean age of the patients was 64.9 ± 8.2 (38 – 86) years. Distribution of concomitant prostate pathologies was benign prostate pathologies in 80 (47.3%), high grade prostatic intraepithelial neoplasia in 38 (22.5%) and prostate cancer in 51 (30.2%) patients. Prostate specific antigen values (3.5 ± 3.0) of patients with prostate cancer were significantly higher than those without prostate cancer (2.6 ± 4.0) (p = 0.014).

DISCUSSION AND CONCLUSION

In the management of male patients who will be operated for bladder cancer, it should be considered that prostate cancer, prostate cancer precursor lesions and prostate invasion might accompany bladder cancer. Prostate should be evaluated in detail before the operation in patients who are planned to undergo prostate-sparing cystectomy. Although the clinical importance of prostate cancer accompanying bladder cancer is controversial, the follow-up of patients with advanced Gleason score in terms of prostate cancer should not be ignored.